Genmab A (GMAB) Receivables - Net (2023 - 2025)

Genmab A has reported Receivables - Net for 3 years, with the latest figure at $1.1 billion in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Net rose 21.94% year-over-year to $1.1 billion; the trailing twelve-month figure through Dec 2025 stood at $1.1 billion (up 21.94% YoY), and the FY2025 full-year result was $1.1 billion, up 21.94% from the prior year.
• Receivables - Net for Q4 2025 stood at $1.1 billion, up from $930.0 million in the prior quarter.
• The five-year high for Receivables - Net was $1.1 billion in Q4 2025, with the low at $743.0 million in Q4 2023.
• Historically, Receivables - Net has averaged $935.7 million across 3 years, with a median of $930.0 million in 2024.
• Annual changes were most pronounced in 2024 — Receivables - Net grew 25.17% — and 2025, when it advanced 21.94%.
• Genmab A's Receivables - Net stood at $743.0 million in 2023, then grew by 25.17% to $930.0 million in 2024, then advanced by 21.94% to $1.1 billion in 2025.
• The last three Receivables - Net figures came in at $1.1 billion (Q4 2025), $930.0 million (Q4 2024), and $743.0 million (Q4 2023), per Business Quant data.